<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01481233</url>
  </required_header>
  <id_info>
    <org_study_id>PSHCI 09-023</org_study_id>
    <nct_id>NCT01481233</nct_id>
  </id_info>
  <brief_title>Oral Colchicine in Men With Castrate Resistant Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Oral Colchicine in Men With Castrate-Resistant Prostate Cancer Who Have Failed Taxotere-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prostate specific antigen response to&#xD;
      continuous low dose oral colchicine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a simple phase II trial of oral colchicine at the standard&#xD;
      prophylactic dose utilized for gout in men with CRPCa who have failed taxotere based&#xD;
      chemotherapy. The investigators will utilize a simple modified Simon 2-stage design. The&#xD;
      investigators plan to enroll 40 men for the study. The men should have completed prior&#xD;
      taxotere based therapy or any other therapy post-taxotere including cabazitaxel one month&#xD;
      prior to receipt of colchicine on trial. Staging with a baseline bone scan, CT and PSA as&#xD;
      well as routine CBC, CMP and PAP. The dose of the drug can be escalated as tolerated to a&#xD;
      maximum of 1.2 mg bid. The patient would be seen at 21 day intervals. After every 3 cycles of&#xD;
      treatment, patient would be restaged with CT and bone scan. Patients with stable disease,&#xD;
      partial response or complete response would continue therapy until either disease progression&#xD;
      or intolerable toxicity after which the patient would be taken off study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Due to funding&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Response rate</measure>
    <time_frame>63 days (3 cycles of treatment)</time_frame>
    <description>Determine the PSA response rate to continuous low dose oral colchicine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>63 days (3 cycles)</time_frame>
    <description>Determine the progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity grading</measure>
    <time_frame>One year</time_frame>
    <description>Determine the safety and tolerability of continuous low dose oral colchicine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg BID x 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.6 mg bid to a maximum of 1.2 mg bid</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Castrate resistant prostate cancer&#xD;
&#xD;
          -  Failure or intolerance of taxotere or cabazitaxel-based chemotherapy or abiraterone&#xD;
             administered for castrate resistant prostate cancer is allowed&#xD;
&#xD;
          -  Age &gt; 18 years and ability to provide informed consent&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          -  No prior use of colchicine within the last 2 years&#xD;
&#xD;
          -  No chemotherapy, hormonal therapy, immunotherapy or radiation therapy within 1 month&#xD;
             of day 1, cycle 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Hypersensitivity to colchicine&#xD;
&#xD;
          -  Severe renal, gastrointestinal or hepatic disorders&#xD;
&#xD;
          -  Pre-existing blood dyscrasia&#xD;
&#xD;
          -  PLT &lt; 100K, ANC &lt; 1000&#xD;
&#xD;
          -  Serum Cr &gt; 2 x ULN&#xD;
&#xD;
          -  Bilirubin &gt; 2 ULN&#xD;
&#xD;
          -  AST &gt; 2 x ULN&#xD;
&#xD;
          -  Concurrent use of CYP3A4 inhibitors which may increase drug levels and toxicity&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Drabick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>September 26, 2013</last_update_submitted>
  <last_update_submitted_qc>September 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Joseph Drabick</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>oral colchicine</keyword>
  <keyword>castrate-resistant prostate cancer</keyword>
  <keyword>failed taxotere based chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

